PriceTargets.com logo

Vaccitech - VACC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $7.63
  • Forecasted Upside: 213.93%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.43 As of 04/25/2024 01:00 AM ET
▼ -0.08 (-3.19%)

This chart shows the closing price for VACC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vaccitech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VACC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VACC

Analyst Price Target is $7.63
▲ +213.93% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Vaccitech in the last 3 months. The average price target is $7.63, with a high forecast of $12.00 and a low forecast of $3.25. The average price target represents a 213.93% upside from the last price of $2.43.

This chart shows the closing price for VACC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in Vaccitech. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/25/2023Alliance Global PartnersInitiated CoverageBuy$12.00Low
9/25/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$14.00 ➝ $3.25Low
8/18/2023Morgan StanleyLower TargetOverweight ➝ Overweight$15.00 ➝ $14.00Low
3/27/2023HC WainwrightLower TargetBuy$20.00 ➝ $15.00Low
3/26/2023BarclaysLower Target$23.00 ➝ $7.00Low
3/21/2023HC WainwrightReiterated RatingBuy$20.00Low
11/14/2022HC WainwrightReiterated RatingBuy$20.00Low
8/15/2022Morgan StanleyLower TargetOverweight$19.00 ➝ $16.00Low
8/11/2022HC WainwrightLower TargetBuy$22.00 ➝ $20.00Low
6/23/2022HC WainwrightReiterated RatingBuy$22.00Low
5/12/2022HC WainwrightLower Target$23.00 ➝ $22.00High
1/19/2022HC WainwrightReiterated RatingBuy$23.00Low
12/15/2021HC WainwrightLower TargetBuy$25.00 ➝ $23.00High
11/15/2021HC WainwrightReiterated RatingBuy$24.00Low
10/22/2021William BlairReiterated RatingBuyLow
7/7/2021HC WainwrightReiterated RatingBuy$25.00Low
5/25/2021William BlairInitiated CoverageOutperformHigh
5/25/2021Jefferies Financial GroupInitiated CoverageBuy$28.00High
5/25/2021Morgan StanleyInitiated CoverageOverweight$22.00High
5/24/2021HC WainwrightInitiated CoverageBuy$25.00Medium
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Vaccitech logo
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: $2.43
Low: $2.40
High: $2.54

50 Day Range

MA: $2.71
Low: $2.33
High: $3.67

52 Week Range

Now: $2.43
Low: $1.64
High: $5.10

Volume

2,824 shs

Average Volume

244,643 shs

Market Capitalization

$93.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vaccitech?

The following sell-side analysts have issued research reports on Vaccitech in the last twelve months: Alliance Global Partners, and Morgan Stanley.
View the latest analyst ratings for VACC.

What is the current price target for Vaccitech?

2 Wall Street analysts have set twelve-month price targets for Vaccitech in the last year. Their average twelve-month price target is $7.63, suggesting a possible upside of 213.9%. Alliance Global Partners has the highest price target set, predicting VACC will reach $12.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $3.25 for Vaccitech in the next year.
View the latest price targets for VACC.

What is the current consensus analyst rating for Vaccitech?

Vaccitech currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for VACC.

What other companies compete with Vaccitech?

Other companies that are similar to Vaccitech include Anixa Biosciences, IO Biotech, Cellectar Biosciences, Barinthus Biotherapeutics and Oramed Pharmaceuticals. Learn More about companies similar to Vaccitech.

How do I contact Vaccitech's investor relations team?

Vaccitech's physical mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The company's listed phone number is 44-18-6581-8808 and its investor relations email address is [email protected].. The official website for Vaccitech is www.vaccitech.co.uk. Learn More about contacing Vaccitech investor relations.